adeno-associated virus vector

AAV vectors are used here as the gene therapy delivery platform whose in vivo transgene expression depends on dosing time. The paper studies how injection timing changes AAV efficacy in mice.

AAV vectors are presented as a major viral delivery system in gene therapy. The abstract links AAV to approved therapy and to dual-AAV strategies for large gene delivery.

The reported use case requires intraperitoneal administration in mice and measurement of transgene expression over several weeks. The abstract does not specify the exact capsid, promoter, or payload.

AAV provides a way to deliver gene therapy cargo and achieve sustained transgene expression in vivo. The study suggests that optimizing dosing time may improve this delivery platform's effective performance.

They provide a clinically relevant vector platform for gene delivery.

The abstract states that AAV gene therapy is still limited by the cost and toxicity of the large doses required. It also does not establish whether the timing effect generalizes beyond the reported mouse intraperitoneal setting.

The abstract mentions other nanoparticle therapies as a broader class that might also benefit from chronopharmacology. It does not name a specific alternative vector platform in the abstract itself.

The abstract contrasts AAV with lentiviral vectors, adenoviral vectors, LNP, and GalNAc-based non-viral approaches.